Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 88 entries
Sorted by: Best Match Show Resources per page
Prevalence of Atherosclerosis in diabetic and non-diabetic patients with rheumatoid arthritis.

Pakistan journal of medical sciences

Kisiel B, Kruszewski R, Juszkiewicz A, Kłos K, Tłustochowicz M, Tłustochowicz W.
PMID: 26648990
Pak J Med Sci. 2015 Sep-Oct;31(5):1078-83. doi: 10.12669/pjms.315.7620.

OBJECTIVES: (1) To compare the prevalence of preclinical atherosclerosis in diabetic vs. non-diabetic rheumatoid arthritis (RA) patients; (2) to determine the influence of classical and RA-related factors on atherosclerosis; (3) to assess the usefulness of combined carotid and femoral...

Cite
Kisiel B, Kruszewski R, Juszkiewicz A, et al. Prevalence of Atherosclerosis in diabetic and non-diabetic patients with rheumatoid arthritis. Pak J Med Sci. 2015;31(5):1078-83doi: 10.12669/pjms.315.7620.
Kisiel, B., Kruszewski, R., Juszkiewicz, A., Kłos, K., Tłustochowicz, M., & Tłustochowicz, W. (2015). Prevalence of Atherosclerosis in diabetic and non-diabetic patients with rheumatoid arthritis. Pakistan journal of medical sciences, 31(5), 1078-83. https://doi.org/10.12669/pjms.315.7620
Kisiel, Bartłomiej, et al. "Prevalence of Atherosclerosis in diabetic and non-diabetic patients with rheumatoid arthritis." Pakistan journal of medical sciences vol. 31,5 (2015): 1078-83. doi: https://doi.org/10.12669/pjms.315.7620
Kisiel B, Kruszewski R, Juszkiewicz A, Kłos K, Tłustochowicz M, Tłustochowicz W. Prevalence of Atherosclerosis in diabetic and non-diabetic patients with rheumatoid arthritis. Pak J Med Sci. 2015 Sep-Oct;31(5):1078-83. doi: 10.12669/pjms.315.7620. PMID: 26648990; PMCID: PMC4641259.
Copy Download .nbib Format: NLM
The structure and energetics of arsenic(III) oxide intercalated by ionic azides.

Dalton transactions (Cambridge, England : 2003)

Guńka PA, Kraszewski K, Chen YS, Zachara J.
PMID: 25017432
Dalton Trans. 2014 Sep 07;43(33):12776-83. doi: 10.1039/c4dt01569j.

Unprecedented intercalates of arsenic(iii) oxide with potassium azide and ammonium azide have been obtained and characterized by single crystal X-ray diffraction. The compounds are built of As2O3 sheets separated by charged layers of cations and azide anions perpendicular to...

Cite
Guńka PA, Kraszewski K, Chen YS, et al. The structure and energetics of arsenic(III) oxide intercalated by ionic azides. Dalton Trans. 2014;43(33):12776-83doi: 10.1039/c4dt01569j.
Guńka, P. A., Kraszewski, K., Chen, Y. S., & Zachara, J. (2014). The structure and energetics of arsenic(III) oxide intercalated by ionic azides. Dalton transactions (Cambridge, England : 2003), 43(33), 12776-83. https://doi.org/10.1039/c4dt01569j
Guńka, Piotr A, et al. "The structure and energetics of arsenic(III) oxide intercalated by ionic azides." Dalton transactions (Cambridge, England : 2003) vol. 43,33 (2014): 12776-83. doi: https://doi.org/10.1039/c4dt01569j
Guńka PA, Kraszewski K, Chen YS, Zachara J. The structure and energetics of arsenic(III) oxide intercalated by ionic azides. Dalton Trans. 2014 Sep 07;43(33):12776-83. doi: 10.1039/c4dt01569j. PMID: 25017432.
Copy Download .nbib Format: NLM
Occurrence of sleep-related breathing disorders in patients with chronic urticaria at its asymptomatic or oligosymptomatic stages.

Postepy dermatologii i alergologii

Perkowska J, Kruszewski J, Gutkowski P, Chciałowski A, Kłos K.
PMID: 26985182
Postepy Dermatol Alergol. 2016 Feb;33(1):63-7. doi: 10.5114/pdia.2015.48052. Epub 2016 Feb 29.

INTRODUCTION: Chronic urticaria (CU), in view of its manifestations (pruritus, wheals), chronic and recurrent nature is very bothersome for patients and significantly influences their quality of life.AIM: To assess the importance of sleep problems and sleep-related breathing disorders (SRBDs)...

Cite
Perkowska J, Kruszewski J, Gutkowski P, et al. Occurrence of sleep-related breathing disorders in patients with chronic urticaria at its asymptomatic or oligosymptomatic stages. Postepy Dermatol Alergol. 2016;33(1):63-7doi: 10.5114/pdia.2015.48052.
Perkowska, J., Kruszewski, J., Gutkowski, P., Chciałowski, A., & Kłos, K. (2016). Occurrence of sleep-related breathing disorders in patients with chronic urticaria at its asymptomatic or oligosymptomatic stages. Postepy dermatologii i alergologii, 33(1), 63-7. https://doi.org/10.5114/pdia.2015.48052
Perkowska, Jolanta, et al. "Occurrence of sleep-related breathing disorders in patients with chronic urticaria at its asymptomatic or oligosymptomatic stages." Postepy dermatologii i alergologii vol. 33,1 (2016): 63-7. doi: https://doi.org/10.5114/pdia.2015.48052
Perkowska J, Kruszewski J, Gutkowski P, Chciałowski A, Kłos K. Occurrence of sleep-related breathing disorders in patients with chronic urticaria at its asymptomatic or oligosymptomatic stages. Postepy Dermatol Alergol. 2016 Feb;33(1):63-7. doi: 10.5114/pdia.2015.48052. Epub 2016 Feb 29. PMID: 26985182; PMCID: PMC4793057.
Copy Download .nbib Format: NLM
Matrix models for quantifying competitive intransitivity.

Oikos (Copenhagen, Denmark)

Ulrich W, Soliveres S, Kryszewski W, Maestre FT, Gotelli NJ.
PMID: 25914427
Oikos. 2014 Sep 01;123(9):1057-1070. doi: 10.1111/oik.01217.

Assessing the relative importance of intransitive competition networks in nature has been difficult because it requires a large number of pairwise competition experiments linked to observed field abundances of interacting species. Here we introduce metrics and statistical tests for...

Cite
Ulrich W, Soliveres S, Kryszewski W, et al. Matrix models for quantifying competitive intransitivity. Oikos. 2014;123(9):1057-1070doi: 10.1111/oik.01217.
Ulrich, W., Soliveres, S., Kryszewski, W., Maestre, F. T., & Gotelli, N. J. (2014). Matrix models for quantifying competitive intransitivity. Oikos (Copenhagen, Denmark), 123(9), 1057-1070. https://doi.org/10.1111/oik.01217
Ulrich, Werner, et al. "Matrix models for quantifying competitive intransitivity." Oikos (Copenhagen, Denmark) vol. 123,9 (2014): 1057-1070. doi: https://doi.org/10.1111/oik.01217
Ulrich W, Soliveres S, Kryszewski W, Maestre FT, Gotelli NJ. Matrix models for quantifying competitive intransitivity. Oikos. 2014 Sep 01;123(9):1057-1070. doi: 10.1111/oik.01217. PMID: 25914427; PMCID: PMC4407980.
Copy Download .nbib Format: NLM
Mitochondrial and nuclear mitoribosomal suppressors that enable misreading of ochre codons in yeast mitochondria : II. Specificity and extent of suppressor action.

Current genetics

Kruszewska A, Slonimski PP.
PMID: 24173505
Curr Genet. 1984 Dec;9(1):11-9. doi: 10.1007/BF00396199.

We describe studies on the action spectra of the mitochondrial suppressor mim3-1 and the three alleles of nuclear suppressor nam3. Their specificity of action was tested on 516 mit (-) mutations located in different mitochondrial genes. The degree of...

Cite
Kruszewska A, Slonimski PP. Mitochondrial and nuclear mitoribosomal suppressors that enable misreading of ochre codons in yeast mitochondria : II. Specificity and extent of suppressor action. Curr Genet. 1984;9(1):11-9doi: 10.1007/BF00396199.
Kruszewska, A., & Slonimski, P. P. (1984). Mitochondrial and nuclear mitoribosomal suppressors that enable misreading of ochre codons in yeast mitochondria : II. Specificity and extent of suppressor action. Current genetics, 9(1), 11-9. https://doi.org/10.1007/BF00396199
Kruszewska, A, and Slonimski, P P. "Mitochondrial and nuclear mitoribosomal suppressors that enable misreading of ochre codons in yeast mitochondria : II. Specificity and extent of suppressor action." Current genetics vol. 9,1 (1984): 11-9. doi: https://doi.org/10.1007/BF00396199
Kruszewska A, Slonimski PP. Mitochondrial and nuclear mitoribosomal suppressors that enable misreading of ochre codons in yeast mitochondria : II. Specificity and extent of suppressor action. Curr Genet. 1984 Dec;9(1):11-9. doi: 10.1007/BF00396199. PMID: 24173505.
Copy Download .nbib Format: NLM
Systematic assessment of the quality of osteoporosis guidelines.

BMC musculoskeletal disorders

Cranney A, Waldegger L, Graham ID, Man-Son-Hing M, Byszewski A, Ooi DS.
PMID: 12174195
BMC Musculoskelet Disord. 2002 Aug 12;3:20. doi: 10.1186/1471-2474-3-20.

BACKGROUND: Numerous agencies have developed clinical practice guidelines for the management of postmenopausal osteoporosis. The study objective was to conduct a systematic assessment of the quality of osteoporosis guidelines produced since 1998.METHODS: Guidelines were identified by searching MEDLINE (1998+),...

Cite
Cranney A, Waldegger L, Graham ID, et al. Systematic assessment of the quality of osteoporosis guidelines. BMC Musculoskelet Disord. 2002;3:20doi: 10.1186/1471-2474-3-20.
Cranney, A., Waldegger, L., Graham, I. D., Man-Son-Hing, M., Byszewski, A., & Ooi, D. S. (2002). Systematic assessment of the quality of osteoporosis guidelines. BMC musculoskeletal disorders, 320. https://doi.org/10.1186/1471-2474-3-20
Cranney, A, et al. "Systematic assessment of the quality of osteoporosis guidelines." BMC musculoskeletal disorders vol. 3 (2002): 20. doi: https://doi.org/10.1186/1471-2474-3-20
Cranney A, Waldegger L, Graham ID, Man-Son-Hing M, Byszewski A, Ooi DS. Systematic assessment of the quality of osteoporosis guidelines. BMC Musculoskelet Disord. 2002 Aug 12;3:20. doi: 10.1186/1471-2474-3-20. PMID: 12174195; PMCID: PMC126217.
Copy Download .nbib Format: NLM
Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology.

Postepy dermatologii i alergologii

Nowicki R, Trzeciak M, Wilkowska A, Sokołowska-Wojdyło M, Ługowska-Umer H, Barańska-Rybak W, Kaczmarski M, Kowalewski C, Kruszewski J, Maj J, Silny W, Śpiewak R, Petranyuk A.
PMID: 26366146
Postepy Dermatol Alergol. 2015 Aug;32(4):239-49. doi: 10.5114/pdia.2015.53319. Epub 2015 Aug 12.

Atopic dermatitis (AD) is a condition frequently encountered in medical practices across the country. More than 60% of children with AD are at risk to develop allergic rhinitis or asthma (the atopic march). Patients with AD have a unique...

Cite
Nowicki R, Trzeciak M, Wilkowska A, et al. Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology. Postepy Dermatol Alergol. 2015;32(4):239-49doi: 10.5114/pdia.2015.53319.
Nowicki, R., Trzeciak, M., Wilkowska, A., Sokołowska-Wojdyło, M., Ługowska-Umer, H., Barańska-Rybak, W., Kaczmarski, M., Kowalewski, C., Kruszewski, J., Maj, J., Silny, W., Śpiewak, R., & Petranyuk, A. (2015). Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology. Postepy dermatologii i alergologii, 32(4), 239-49. https://doi.org/10.5114/pdia.2015.53319
Nowicki, Roman, et al. "Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology." Postepy dermatologii i alergologii vol. 32,4 (2015): 239-49. doi: https://doi.org/10.5114/pdia.2015.53319
Nowicki R, Trzeciak M, Wilkowska A, Sokołowska-Wojdyło M, Ługowska-Umer H, Barańska-Rybak W, Kaczmarski M, Kowalewski C, Kruszewski J, Maj J, Silny W, Śpiewak R, Petranyuk A. Atopic dermatitis: current treatment guidelines. Statement of the experts of the Dermatological Section, Polish Society of Allergology, and the Allergology Section, Polish Society of Dermatology. Postepy Dermatol Alergol. 2015 Aug;32(4):239-49. doi: 10.5114/pdia.2015.53319. Epub 2015 Aug 12. PMID: 26366146; PMCID: PMC4565838.
Copy Download .nbib Format: NLM
Silver, Gold, and Iron Oxide Nanoparticles Alter miRNA Expression but Do Not Affect DNA Methylation in HepG2 Cells.

Materials (Basel, Switzerland)

Brzóska K, Grądzka I, Kruszewski M.
PMID: 30934809
Materials (Basel). 2019 Mar 29;12(7). doi: 10.3390/ma12071038.

The increasing use of nanoparticles (NPs) in various applications entails the need for reliable assessment of their potential toxicity for humans. Originally, studies concerning the toxicity of NPs focused on cytotoxic and genotoxic effects, but more recently, attention has...

Cite
Brzóska K, Grądzka I, Kruszewski M. Silver, Gold, and Iron Oxide Nanoparticles Alter miRNA Expression but Do Not Affect DNA Methylation in HepG2 Cells. Materials (Basel). 2019;12(7)doi: 10.3390/ma12071038.
Brzóska, K., Grądzka, I., & Kruszewski, M. (2019). Silver, Gold, and Iron Oxide Nanoparticles Alter miRNA Expression but Do Not Affect DNA Methylation in HepG2 Cells. Materials (Basel, Switzerland), 12(7), . https://doi.org/10.3390/ma12071038
Brzóska, Kamil, et al. "Silver, Gold, and Iron Oxide Nanoparticles Alter miRNA Expression but Do Not Affect DNA Methylation in HepG2 Cells." Materials (Basel, Switzerland) vol. 12,7 (2019). doi: https://doi.org/10.3390/ma12071038
Brzóska K, Grądzka I, Kruszewski M. Silver, Gold, and Iron Oxide Nanoparticles Alter miRNA Expression but Do Not Affect DNA Methylation in HepG2 Cells. Materials (Basel). 2019 Mar 29;12(7). doi: 10.3390/ma12071038. PMID: 30934809; PMCID: PMC6479689.
Copy Download .nbib Format: NLM
Driving and Dementia: Workshop Module on Communicating Cessation to Drive.

Canadian geriatrics journal : CGJ

Byszewski A, Power B, Lee L, Rhee GG, Parson B, Molnar F.
PMID: 29296130
Can Geriatr J. 2017 Dec 22;20(4):241-245. doi: 10.5770/cgj.20.264. eCollection 2017 Dec.

BACKGROUND: For persons with dementia (PWD), driving becomes very dangerous. Physicians in Canada are legally responsible to report unfit drivers and then must disclose that decision to their patients. That difficult discussion is fraught with challenges: physicians want to...

Cite
Byszewski A, Power B, Lee L, et al. Driving and Dementia: Workshop Module on Communicating Cessation to Drive. Can Geriatr J. 2017;20(4):241-245doi: 10.5770/cgj.20.264.
Byszewski, A., Power, B., Lee, L., Rhee, G. G., Parson, B., & Molnar, F. (2017). Driving and Dementia: Workshop Module on Communicating Cessation to Drive. Canadian geriatrics journal : CGJ, 20(4), 241-245. https://doi.org/10.5770/cgj.20.264
Byszewski, Anna, et al. "Driving and Dementia: Workshop Module on Communicating Cessation to Drive." Canadian geriatrics journal : CGJ vol. 20,4 (2017): 241-245. doi: https://doi.org/10.5770/cgj.20.264
Byszewski A, Power B, Lee L, Rhee GG, Parson B, Molnar F. Driving and Dementia: Workshop Module on Communicating Cessation to Drive. Can Geriatr J. 2017 Dec 22;20(4):241-245. doi: 10.5770/cgj.20.264. eCollection 2017 Dec. PMID: 29296130; PMCID: PMC5740947.
Copy Download .nbib Format: NLM
Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials.

Postepy dermatologii i alergologii

Abramowicz M, Kruszewski J, Chciałowski A.
PMID: 30618532
Postepy Dermatol Alergol. 2018 Dec;35(6):620-625. doi: 10.5114/ada.2018.77614. Epub 2018 Nov 13.

INTRODUCTION: The total effect of the method of treatment is composed of its specific activity depending on its impact on the disease mechanism and the non-specific activity, i.e. the placebo effect. Many methods of treatment make use of such...

Cite
Abramowicz M, Kruszewski J, Chciałowski A. Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials. Postepy Dermatol Alergol. 2018;35(6):620-625doi: 10.5114/ada.2018.77614.
Abramowicz, M., Kruszewski, J., & Chciałowski, A. (2018). Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials. Postepy dermatologii i alergologii, 35(6), 620-625. https://doi.org/10.5114/ada.2018.77614
Abramowicz, Michał, et al. "Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials." Postepy dermatologii i alergologii vol. 35,6 (2018): 620-625. doi: https://doi.org/10.5114/ada.2018.77614
Abramowicz M, Kruszewski J, Chciałowski A. Evaluation of the placebo effect in the trials of allergen immunotherapy effectiveness: meta-analysis of randomized and placebo-controlled trials. Postepy Dermatol Alergol. 2018 Dec;35(6):620-625. doi: 10.5114/ada.2018.77614. Epub 2018 Nov 13. PMID: 30618532; PMCID: PMC6320494.
Copy Download .nbib Format: NLM
Polymer Membranes Sonocoated and Electrosprayed with Nano-Hydroxyapatite for Periodontal Tissues Regeneration.

Nanomaterials (Basel, Switzerland)

Higuchi J, Fortunato G, Woźniak B, Chodara A, Domaschke S, Męczyńska-Wielgosz S, Kruszewski M, Dommann A, Łojkowski W.
PMID: 31731775
Nanomaterials (Basel). 2019 Nov 15;9(11). doi: 10.3390/nano9111625.

Diseases of periodontal tissues are a considerable clinical problem, connected with inflammatory processes and bone loss. The healing process often requires reconstruction of lost bone in the periodontal area. For that purpose, various membranes are used to prevent ingrowth...

Cite
Higuchi J, Fortunato G, Woźniak B, et al. Polymer Membranes Sonocoated and Electrosprayed with Nano-Hydroxyapatite for Periodontal Tissues Regeneration. Nanomaterials (Basel). 2019;9(11)doi: 10.3390/nano9111625.
Higuchi, J., Fortunato, G., Woźniak, B., Chodara, A., Domaschke, S., Męczyńska-Wielgosz, S., Kruszewski, M., Dommann, A., & Łojkowski, W. (2019). Polymer Membranes Sonocoated and Electrosprayed with Nano-Hydroxyapatite for Periodontal Tissues Regeneration. Nanomaterials (Basel, Switzerland), 9(11), . https://doi.org/10.3390/nano9111625
Higuchi, Julia, et al. "Polymer Membranes Sonocoated and Electrosprayed with Nano-Hydroxyapatite for Periodontal Tissues Regeneration." Nanomaterials (Basel, Switzerland) vol. 9,11 (2019). doi: https://doi.org/10.3390/nano9111625
Higuchi J, Fortunato G, Woźniak B, Chodara A, Domaschke S, Męczyńska-Wielgosz S, Kruszewski M, Dommann A, Łojkowski W. Polymer Membranes Sonocoated and Electrosprayed with Nano-Hydroxyapatite for Periodontal Tissues Regeneration. Nanomaterials (Basel). 2019 Nov 15;9(11). doi: 10.3390/nano9111625. PMID: 31731775; PMCID: PMC6915502.
Copy Download .nbib Format: NLM
Mechanism of Iodine(III)-Promoted Oxidative Dearomatizing Hydroxylation of Phenols: Evidence for a Radical-Chain Pathway.

Chemistry (Weinheim an der Bergstrasse, Germany)

Kraszewski K, Tomczyk I, Drabinska A, Bienkowski K, Solarska R, Kalek M.
PMID: 32608529
Chemistry. 2020 Sep 04;26(50):11584-11592. doi: 10.1002/chem.202002026. Epub 2020 Aug 10.

The oxidative dearomatization of phenols with the addition of nucleophiles to the aromatic ring induced by hypervalent iodine(III) reagents and catalysts has emerged as a highly useful synthetic approach. However, experimental mechanistic studies of this important process have been...

Cite
Kraszewski K, Tomczyk I, Drabinska A, et al. Mechanism of Iodine(III)-Promoted Oxidative Dearomatizing Hydroxylation of Phenols: Evidence for a Radical-Chain Pathway. Chemistry. 2020;26(50):11584-11592doi: 10.1002/chem.202002026.
Kraszewski, K., Tomczyk, I., Drabinska, A., Bienkowski, K., Solarska, R., & Kalek, M. (2020). Mechanism of Iodine(III)-Promoted Oxidative Dearomatizing Hydroxylation of Phenols: Evidence for a Radical-Chain Pathway. Chemistry (Weinheim an der Bergstrasse, Germany), 26(50), 11584-11592. https://doi.org/10.1002/chem.202002026
Kraszewski, Karol, et al. "Mechanism of Iodine(III)-Promoted Oxidative Dearomatizing Hydroxylation of Phenols: Evidence for a Radical-Chain Pathway." Chemistry (Weinheim an der Bergstrasse, Germany) vol. 26,50 (2020): 11584-11592. doi: https://doi.org/10.1002/chem.202002026
Kraszewski K, Tomczyk I, Drabinska A, Bienkowski K, Solarska R, Kalek M. Mechanism of Iodine(III)-Promoted Oxidative Dearomatizing Hydroxylation of Phenols: Evidence for a Radical-Chain Pathway. Chemistry. 2020 Sep 04;26(50):11584-11592. doi: 10.1002/chem.202002026. Epub 2020 Aug 10. PMID: 32608529.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 88 entries